Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
Silverberg J, Gooderham M, Paller A, Deleuran M, Bunick C, Gold L, Hijnen D, Calimlim B, Lee W, Teixeira H, Hu X, Zhang S, Yang Y, Grada A, Platt A, Thaçi D. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2). American Journal Of Clinical Dermatology 2024, 25: 485-496. PMID: 38528257, PMCID: PMC11070400, DOI: 10.1007/s40257-024-00853-4.Peer-Reviewed Original ResearchPatient Global ImpressionModerate-to-severe atopic dermatitisPatients treated with upadacitinibPatient-reported outcomesGlobal ImpressionAtopic dermatitisWeek 1Skin symptomsQuality of lifeTreating moderate-to-severe atopic dermatitisPhase III monotherapy trialsPhase III randomized clinical trialsWeek 8Baseline to week 1Pruritus Numerical Rating ScaleScoring Atopic Dermatitis indexEffect of upadacitinibOral selective Janus kinaseAtopic Dermatitis indexAssessed patient-reported outcomesMinimal clinically important differenceNumerical rating scaleDermatology Life Quality IndexPatient-Oriented Eczema MeasureChronic inflammatory disease